AcipHex.com—Talk to Your Doctor

Important Safety Information / Full Product Information

During an interview with leading gastroenterologist, Dr Ronnie Fass,* MD, FACP, FACG, we asked him what tests doctors might use to confirm the condition or determine the damage to the esophagus. To hear what he had to say, play the video.

To use this feature, Adobe® Flash® Player must be installed on your computer. If you do not have this program, click here to get it.

Adobe, the Adobe logo, and Flash are registered trademarks of Adobe Systems Incorporated in the United States and/or other countries.

*	Dr Fass is a paid consultant of Eisai Inc. and PRICARA,^® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

NextRelief and ACIPHEX >

One ACIPHEX 20 mg tablet daily is used for the treatment of persistent, frequent (2 or more days a week) heartburn and other symptoms associated with acid reflux disease.

ACIPHEX is also used for the short-term (4 to 8 weeks) treatment in the healing and symptom relief of damaging (erosive) acid reflux disease (gastroesophageal reflux disease) and to maintain healing of damage (erosions) and relief of heartburn symptoms that happen with acid reflux disease. ACIPHEX has not been studied for treatment lasting longer than 12 months (1 year).

ACIPHEX is approved for adults only.

Important Safety Information
ACIPHEX has a well-established safety profile. The most common side effect possibly related to ACIPHEX is headache. Symptom relief does not rule out other serious stomach conditions. Patients on warfarin (such as Coumadin^®) may need to be monitored more closely by their doctors. To learn more, talk to your doctor and see the Full Product Information.

ACIPHEX is a registered trademark of Eisai Company, Ltd., Tokyo, Japan.
©2008 Eisai Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1998-2008. This site originates in the United States.

This information is intended for use by our customers, patients, healthcare professionals and interested parties in the United States only. Eisai Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognize that the internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here is not appropriate for use outside the United States.

This site contains information about products that may have different product labeling in different countries. This site is intended for adults 18 years and older.

This site is published by Eisai Inc. and PriCara Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which are solely responsible for its contents.

Coumadin is a registered trademark of Bristol-Myers Squibb Company.

This site was last modified on: March 25, 2008 at 5:30:00 EST

01AX1542